evidence/gaps
Cochrane · systematic review · CD008559

Atypical antipsychotics for disruptive behaviour disorders in children and youths

Loy, JH, Merry, SN, Hetrick, SE, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library

Developmental, Psychosocial and Learning Problems2 versionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 40%Moderate 3 · 60%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Show all 2 versions

Risperidone compared to placebo for disruptive behaviours in children and youths

Population: Disruptive behaviours in children and youths
5 questions
OutcomeEffectEvidenceStatus / GRADE
Aggression
Risperidone vs placebo
no estimate extracted3 studies · 238 participantsLow
Downgraded: risk of bias, imprecision
Aggression
Risperidone vs placebo
no estimate extracted2 studies · 190 participantsModerate
Downgraded: risk of bias, imprecision, inconsistency
Conduct
Risperidone vs placebo
no estimate extracted2 studies · 225 participantsModerate
Downgraded: risk of bias, imprecision, inconsistency
Weight gain (treatment with antipsychotic only)
Risperidone vs placebo
no estimate extracted2 studies · 138 participantsModerate
Downgraded: risk of bias, imprecision, inconsistency
Weight gain (treatment with antipsychotic and stimulant)
Risperidone vs placebo
no estimate extracted3 studies · 305 participantsLow
Downgraded: risk of bias, imprecision, inconsistency